Unknown

Dataset Information

0

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.


ABSTRACT: Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variety of cancer types have paved the way for new immune therapy trials in brain tumor patients. However, the molecular mechanisms that regulate expression of the PD-1 pathway ligands, PD-L1 and PD-L2, remain poorly understood. To address this, we explored the cell-intrinsic mechanisms of constitutive PD-L1 and PD-L2 expression in brain tumors. PD-L1 and PD-L2 expression was assessed by flow cytometry and qRT-PCR in brain tumor cell lines and patient tumor-derived brain tumor-initiating cells (BTICs). Immunologic effects of PD-L2 overexpression were evaluated by IFN-? ELISPOT. CD274 and PDCD1LG2 cis-regulatory regions were cloned from genomic DNA and assessed in full or by mutating and/or deleting regulatory elements by luciferase assays. Correlations between clinical responses and PD-L1 and PD-L2 expression status were evaluated in TCGA datasets in LGG and GBM patients. We found that a subset of brain tumor cell lines and BTICs expressed high constitutive levels of PD-L1 and PD-L2 and that PD-L2 overexpression inhibited neoantigen specific T cell IFN-? production. Characterization of novel cis-regulatory regions in CD274 and PDCD1LG2 lead us to identify that GATA2 is sufficient to drive PD-L1 and PD-L2 expression and is necessary for PD-L2 expression. Importantly, in TCGA datasets, PD-L2 correlated with worse clinical outcomes in glioma patients.. By perturbing GATA2 biology, targeted therapies may be useful to decrease inhibitory effects of PD-L2 in the microenvironment.

SUBMITTER: Fu Y 

PROVIDER: S-EPMC7271235 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variety of cancer types have paved the way for new immune therapy trials in brain tumor patients. However, the molecular mechanisms that regulate expression of the PD-1 pathway ligands, PD-L1 and PD-L2, remain poorly understood. To address this, we explored the cell-intrinsic mechanisms of constitutive PD-L1 and PD-L2 expression in brain tumors. PD-L1 and PD-L2 expression was assessed by flow cytometry an  ...[more]

Similar Datasets

| S-EPMC4322919 | biostudies-literature
| S-EPMC6420824 | biostudies-literature
| S-EPMC7793653 | biostudies-literature
| S-EPMC5733602 | biostudies-literature
| S-EPMC8794171 | biostudies-literature
| S-EPMC6545701 | biostudies-literature
| S-EPMC6076347 | biostudies-literature
| S-EPMC8656419 | biostudies-literature
| S-EPMC6287426 | biostudies-other
| S-EPMC5629259 | biostudies-other